Development of a new, rapid and sensitive HPTLC method for estimation of Milnacipran in bulk, formulation and compatibility study  by Singhvi, Gautam et al.
Arabian Journal of Chemistry (2013) xxx, xxx–xxxKing Saud University
Arabian Journal of Chemistry
www.ksu.edu.sa
www.sciencedirect.comORIGINAL ARTICLEDevelopment of a new, rapid and sensitive HPTLC
method for estimation of Milnacipran in bulk,
formulation and compatibility studyGautam Singhvi *, Vipin Kumar Shukla, Ravi Ukawala, Gautham Gampa,
Ranendra Narayan SahaDepartment of Pharmacy, Birla Institute of Technology and Science, Pilani, Rajasthan 333 031, IndiaReceived 9 March 2013; accepted 1 September 2013*
E
gm
ga
Pe
18
ht
P
bKEYWORDS
HPTLC;
Milnacipran;
Validation;
Preformulation;
Low costCorresponding author. Tel.
-mail addresses: singhvigauta
ail.com (V.K. Shukla), r.
utham369@gmail.com (G. Ga
er review under responsibilit
Production an
78-5352 ª 2013 Production
tp://dx.doi.org/10.1016/j.arab
lease cite this article in press
ulk, formulation and compat: +91 93
m@gma
d.ukawala
mpa), rnsa
y of King
d hostin
and hosti
jc.2013.0
as: Singh
ibility stuAbstract A simple, sensitive and rapid high performance thin layer chromatographic (HPTLC)
method has been developed and validated for quantitative determination of Milnacipran Hydro-
chloride (MIL) in bulk and formulations. The chromatographic development was carried out on
HPTLC plates precoated with silica gel 60 F254 using a mixture of acetonitrile, water and ammonia
(6:0.6:1.6) (v/v/v) as mobile phase. Detection was carried out densitometrically at 220 nm. The Rf
value of drug was found to be 0.63 ± 0.02. The method was validated as per ICH guideline with
respect to linearity, accuracy, precision, robustness etc. The calibration curve was found to be linear
over a range of 100–1000 ng lL1 with a regression coefﬁcient of 0.999. The accuracy was found to
be very high (99.12–100.87%). %RSD values for intra-day and inter-day variation were not more
than 1.43. The method has demonstrated high sensitivity and speciﬁcity. The method was applied
for compatibility studies also. The method is new, simple and economic for routine estimation of
MIL in bulk, preformulation studies and pharmaceutical formulation to help the industries as well
as researchers for their sensitive determination of MIL rapidly at low cost in routine analysis.
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Milnacipran Hydrochloride (MIL) is a serotonin–norepineph-
rine reuptake inhibitor (SNRI) used as an antidepressant syn-
thesized, developed and marketed by Pierre Fabre
Me´dicament (Boyer and Briley, 1998). It has been approved
by the Food and Drug Administration (FDA) in January 2009
for the management of ﬁbromyalgia syndrome, characterized
by widespread pain and decreased physical function (Kranzler
and Gendreau, 2010). Inhibition of both neurotransmitters
simultaneously works synergistically to treat both depressioning Saud University.
, rapid and sensitive HPTLC method for estimation of Milnacipran in
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.004
2 G. Singhvi et al.and ﬁbromyalgia. Unlike the tricyclic antidepressants (TCAs),
MIL has no signiﬁcant direct action on adrenergic, muscarinic,
or histaminergic receptors – pharmacologic actions associated
with many of the unpleasant side effects of TCAs (Puozzo
et al., 1998, 2002). MIL (Fig. 1) is highly water soluble, leading
to rapid and wide absorption, with maximum concentration ob-
served within 2–4 h after dosing. The bioavailability of MIL is
high (approximately 85–90%), and absorption is not affected
by food intake. MIL undergoes minimal ﬁrst-pass metabolism,
with approximately 55% of the drug excreted unchanged in ur-
ine. Its relatively short half-life (approximately 6–8 h) is compat-
ible with the recommended twice-daily dosing (Puozzo et al.,
2002).
Extensive literature survey revealed that there is no ofﬁcial
high performance thin layer chromatography (HPTLC) meth-
od reported in major pharmacopeias like USP, EP, JP, BP and
IP. There are very few analytical methods available for estima-
tion of MIL alone. Some liquid chromatographic (LC) meth-
ods for determination of MIL combined with many other
antidepressants in human plasma have already been published
(Lacassie et al., 2000; Duverneuil et al., 2003). A micellar elec-
tro-kinetic capillary chromatographic method was developed
for separation and determination of antidepressants and their
metabolites in biological ﬂuids (Labat et al., 2002). A liquid
chromatography with spectroﬂuorimetric detection (Puozzo
et al., 2004) and one GC–MS method is reported for determi-
nation of MIL in human plasma (Ucakturk and Safak, 2010).
Recently, there are a few references for LC and UV spectro-
scopic methods that are published for determination of MIL
in aqueous matrix and pharmaceuticals (Mehta and Khatri,
2010; Dias et al., 2010; Parejiya et al., 2011; Singhvi et al.,
2013) but with sensitivity in microgram levels.
The above literature revealed that all available methods are
sensitive up to microgram level only or need some complex
reactions or require large amount of organic solvents or re-
quire sophisticated instrument or costly in determination of
MIL in routine analysis.
Nowadays, HPTLC has become a routine analytical tech-
nique due to its advantages of reliability in quantitation of
analytes at micro and even in nanogram levels and cost effec-
tiveness. The major advantage of HPTLC is that several sam-
ples can be analyzed simultaneously using a small quantity of
mobile phase unlike HPLC. This reduces the time and cost of
analysis. In addition, it minimizes exposure risks and signiﬁ-
cantly reduces disposal problems of toxic organic efﬂuents,
thereby reducing possibilities of environment pollution.
HPTLC also facilitates repeated detection (scanning) of the
chromatogram with same or different parameters. Simulta-
neous assay of several components in a multi component for-Figure 1 Chemical structure of Milnacipran.
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2011; Shewiyo et al., 2012).
The objective of the present study was to develop and val-
idate a new, simple, accurate, speciﬁc and reproducible
HPTLC method for determination of MIL in bulk, preformu-
lation studies and pharmaceutical formulation to help the
industries as well as researchers for their sensitive determina-
tion of MIL rapidly at low cost in routine analysis.
2. Experimental
2.1. Reagents and chemicals
Milnacipran Hydrochloride was obtained as a gift sample from
Torrent Pharmaceuticals Limited (Ahmedabad, India). All
chemicals used were of analytical grade and solvents were of
HPLC grade. Methanol, acetonitrile, triethylamine, ammonia
and orthophosphoric acid were procured from Merck (India).
Ultrapure water (Milli-Q Plus, Millipore, India) was used
throughout the analysis.
2.2. Instrumentation and chromatographic conditions
Chromatography was performed on 5 cm · 5 cm aluminum
foil plates precoated with 0.2 mm layers of silica gel 60 F254
(E. Merck, Germany). Before use, the plates were prewashed
with methanol and water mixture then dried in the current
of dry air and activated at 120 C for 5 min. Samples were ap-
plied as bands 6 mm wide, 15 mm apart, by use of a CAMAG
(Switzerland) Linomat 5 applicator with a CAMAG microliter
syringe. A constant application rate of 150 nL s1 was used.
Different mobile phases containing water, chloroform, metha-
nol, acetonitrile, acetone, ethyl acetate, dichloro methane,
ammonia, triethylamine in different proportions were exam-
ined. Of these, the mixture of acetonitrile, water and ammonia
(6:0.6:1.6) (v/v/v) was found to be most suitable for the studies.
The Retardation Factor (Rf) value of MIL was found to be
0.63 ± 0.02 in optimized mobile phase. The densitogram ob-
tained from a standard solution of MIL is shown in Fig. 2.
Linear ascending development was performed in a twin-
trough glass chamber previously saturated with mobile phase
vapor for 1.5 min at room temperature (RT, 25 ± 2 C) and rel-
ative humidity 60 ± 5%. The development distance was
approximately 40 mm. After development, the plates were dried
in an oven at 120 C. Densitometric scanning, at 220 nm, was
performedwith a CAMAGTLC scanner 3 in absorbancemode.
The source of radiation was a deutrium lamp emitting a contin-
uous UV spectrum in the range of 190–400 nm.
2.3. Calibration curve and linearity
A stock solution containing 100 lg/mL of MIL was prepared
by dissolving an accurately weighed 10 mg portion of the drug
in methanol in a 10 mL volumetric ﬂask. Different volumes of
stock solution (0.1, 0.3, 0.4, 0.6, 0.8 and 1 lL) were spotted on
an HPTLC plate in triplicate to obtain concentrations of 100,
300, 400, 600, 800 and 1000 ng/band, respectively. The data of
peak area versus drug concentration were treated by linear
least-squares regression. Three quality control level, Lower
quality control samples (LQC) = 200 ng/band, medium qual-
ity control samples (MQC) = 500 ng/band, and higher quality, rapid and sensitive HPTLC method for estimation of Milnacipran in
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.004
Figure 2 Chromatogram of standard Milnacipran: peak of 500 ng (Rf = 0.63).
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various validation studies.
3. Method validation
The analytical method was validated for speciﬁcity, sensitivity,
accuracy, precision, robustness, and ruggedness in accordance
with ICH guidelines (ICH: Q2(R1)).
3.1. Speciﬁcity and sensitivity
The speciﬁcity of the developed method was established ana-
lyzing the sample solutions containing MIL standard and mar-
keted tablets in relation to interferences from formulation
ingredients. The spot for MIL in the sample was conﬁrmed
by comparing Rf values of the spot with that of the standard.
The sensitivity of measurement was estimated in terms of
the limit of quantiﬁcation (LOQ) and the limit of detection
(LOD). The LOQ and LOD were calculated by the use of
equations LOD= 3 · N/B and LOQ= 10 · N/B where N is
the standard deviation of the peak area of the drug (n= 3), ta-
ken as a measure of noise and B is the slope of the correspond-
ing calibration plot.
3.2. Accuracy
To check the accuracy of the method, recovery measurements
were performed by the addition of a standard drug solution at
three different levels (50%, 100% and 150%) to a pre-analyzed
sample solution (200 ng/band so that after addition of stan-
dards, samples would be in the linear range). Three replicate
estimations were carried out for each concentration level.
3.3. Precision
Precision of the method, determined from replicate analysis of
the sample, was expressed as repeatability (intra-batch) and
intermediate precision (inter-batch). The intra-day andPlease cite this article in press as: Singhvi, G. et al., Development of a new
bulk, formulation and compatibility study. Arabian Journal of Chemistryinter-day precision studies were carried out by estimating the
responses of three quality control (QC) standards in triplicates
under same experimental conditions three times on the same
day and on three different days. From the results obtained,
the precision was expressed as percentage relative standard
deviations (%RSD) from mean intra and inter-day assays.
3.4. Robustness and ruggedness
Robustness of the method was performed by spotting 900 ng
of drug making small deliberate changes in various chromato-
graphic conditions. The composition of the mobile phase,
amount of mobile phase (10 ± 2 mL) and duration of satura-
tion (20 ± 10 min) were varied. Time from application of MIL
to the TLC plate to development of the plate and time from
development of plate to scanning were also varied
(20 ± 10 min).
Ruggedness of the method was performed by spotting
900 ng of drug by two different analysts maintaining same
experimental and environmental conditions.
3.5. Stability studies
To test the stability of the drugs on the TLC plates, the freshly
prepared solutions of the analyte were applied to the plates
and developed plates were scanned at different intervals of 2,
6, 24, 48 and 72 h.
3.6. Method application
3.6.1. Analysis of MIL in marketed and in-house tablet dosage
form
To determine the MIL content of marketed capsule dosage
form and in-house tablets, powder equivalent to 10 mg of
MIL was transferred to a 100 mL volumetric ﬂask, extracted
with methanol, sonicated for 15 min, and diluted to volume
with same solvent. The resulting solution was ﬁltered through
a 0.45 lm ﬁlter (Milliﬁlter; Milford, MA; USA). The solution, rapid and sensitive HPTLC method for estimation of Milnacipran in
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.004
Figure 3 3D graph of calibration linearity graph: 100–1000 ng of
milncipran with Rf at 0.63 ± 0.02, showing the peak linearity.
4 G. Singhvi et al.(5 lL, 500 ng MIL) was applied in triplicate on an HPTLC
plate for quantiﬁcation using the proposed method.
3.6.2. Application in drug-excipient compatibility study
The developed method was implemented for compatibility
studies of MIL with various excipients for formulation design.
Drug and excipients were stored in various storage conditions
as per ICH guideline (ICH, Q1A(R2)). Samples were analyzed
for assay at various time points (initial, 1st month, 2nd month
and after 3rd month).
4. Results and discussion
4.1. Calibration curve and linearity
A calibration curve was constructed by plotting peak area
against concentration of Milnacipran (ng per spot). The results
of regression analysis are shown in Table 1. They conﬁrm the
linearity of the standard curves over the range studied (100–
1000 ng/mL). Linear regression of concentration versus peak
area plots resulted in an average coefﬁcient of determination
(r2) greater than 0.999. The average equation for calibration
curves was y= 3.271 x+ 1933. The 3-D chromatographs of
all calibration concentrations and QC samples (LQC, MQC
and HQC) are shown in Figs. 3 and 4, respectively.
4.2. Speciﬁcity and sensitivity
The peak purity of MIL was assessed by comparing the spectra
at three different levels, that is, peak start (S), peak apex (M),
and peak end (E) positions of the spot and the results obtained
as r2 (S, M)= 0.997 and r2 (M, E)= 0.998. Good correlation
was obtained between standard and sample spectra of MIL.
Limit of Detection and Limit of quantiﬁcation were found
to be 25.14 ng and 76.20 ng, respectively. Hence the method
was found to be highly sensitive for determination of MIL.
4.3. Accuracy
The developed method showed high and consistent recoveries
at all studied levels. The results obtained from recovery studies
are presented in Table 2. The mean % recovery ranged from
99.12% to 100.87%. Additionally, the obtained recoveries
were found to be normally distributed with low %RSD
(61.261) at all concentration levels.Table 1 Results of regression analysis of linearity data and
sensitivity of Milnacipran.
Parameter Value
Linearity range (ng/mL) 100–1000 ng
Correlation coeﬃcient (r2) 0.999
Slope (m) ±%RSD 3.271 ± 0.92
Intercept (c) ±%RSD 1933 ± 1.05
Rf 0.63 ± 0.02
LOD (ng/mL) 25.14
LOQ (ng/mL) ±%RSD 76.20 ± 0.95
Ruggedness (%RSD) 1.25
Figure 4 3D chromatographs of quality control concentrations
(LQC: 200 ng, MQC:500 ng and HQC: 900 ng).
Please cite this article in press as: Singhvi, G. et al., Development of a new
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%RSD values for intra-day variation were not more than 1.43
and for inter-day variation were not more than 1.076. Low
%RSD values indicated the good repeatability and intermedi-
ate precision of the method as shown in Table 3.
4.5. Robustness and ruggedness
The results obtained in the new conditions were in accordance
with the original results as shown in Table 4, though the Rf, rapid and sensitive HPTLC method for estimation of Milnacipran in
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.004
Table 2 Results of recovery studies of Milnacipran.
Spiked conc. (%) Theoretical content (ng/band) % Recovery ± S.D RSD (%) % Bias
50 300 99.12 ± 3.75 1.261 0.88
100 400 100.87 ± 3.62 0.897 0.87
150 500 100.53 ± 1.25 0.249 0.53
Table 3 Results of precision study of Milnacipran.
Concentration (ng/band) Intraday Interday
% Recovery (±SD) %RSD % Recovery (±SD) %RSD
LQC (200) 99.84 ± 2.86 1.43 99.89 ± 2.15 1.076
MQC(500) 100.10 ± 0.93 0.18 100.14 ± 1.04 0.207
HQC(900) 99.93 ± 0.57 0.06 99.94 ± 0.85 0.095
Table 4 Results of robustness, ruggedness and stability studies of Milnacipran.
Parameters % Mean recovery ± SD % Bias % RSD
Mobile phase composition
(6.1:0.6:1.6) 99.25 ± 1.35 0.75 0.767
(6:0.5:1.6) 98.47 ± 3.21 1.53 0.362
Mobile phase volume 100.72 ± 1.24 0.72 0.137
Chamber saturation time 99.85 ± 1.57 0.15 0.175
Time of drug application to TLC plate development 99.68 ± 0.58 0.32 0.065
Time of TLC plate development to scanning 100.15 ± 2.87 0.15 0.320
Change of analyst 99.85 ± 4.45 0.15 0.495
Stability up to 72 h 98.75 ± 2.93 1.25 0.330
Table 5 Results of Milnacipran-excipient compatibility study (3rd month data).
Sample* Long term 25 C/60% RH Accelerate condition 40/75% RH
Assay** ± SD Assay** ± SD
Pure drug 99.25 ± 1.50 99.05 ± 1.38
D+Micro crystalline cellulose 99.12 ± 2.34 98.25 ± 0.96
D+ Dibasic calcium phosphate 100.40 ± 0.80 99.12 ± 1.50
D+ Poly vinylpyrrolidone 99.05 ± 1.15 98.17 ± 0.75
D+ HPMC 15 K 100.62 ± 1.15 99.72 ± 2.72
D+Magnesium stearate 100.03 ± 2.34 98.14 ± 1.25
D+ Talc 100.62 ± 1.85 99.45 ± 0.93
* The Rf (± SD) of all compatibility samples were found to be 0.63 ± 0.03.
** All the assay values were calculated with respect to initial assay (100%).
Development of a new, rapid and sensitive HPTLC method for estimation of Milnacipran in bulk 5varied very slightly (0.63 ± 0.3). The %RSD values for peak
area was less than 1.0 indicating the highly robust nature of
the developed method. The %RSD was found to be less than
2% indicating the method was rugged when estimation was
done by two different analysts (Table 4).
4.6. Stability studies
There was no signiﬁcant deviation in peak area (RSD< 1.5%)
observed on analysis up to 72 h. No decomposition of the drug
was observed during chromatogram development. ThesePlease cite this article in press as: Singhvi, G. et al., Development of a new
bulk, formulation and compatibility study. Arabian Journal of Chemistryobservations suggest that the drug is stable under the typical
processing and storage conditions of the analytical procedure.
4.7. Method application
4.7.1. Analysis of MIL in marketed and in-house formulations
Drug bands at Rf 0.65 corresponding to MIL were observed in
chromatograms obtained from tablet extracts. There was no
interference from excipients present in the tablets. The assay
of marketed capsules and in-house tablets was found to be
99.68% (SD ± 1.35) and 100.18 (SD ± 1.65), respectively., rapid and sensitive HPTLC method for estimation of Milnacipran in
(2013), http://dx.doi.org/10.1016/j.arabjc.2013.09.004
6 G. Singhvi et al.The good performance of the method indicated the suitability
of this method for routine analysis of MIL determination in
pharmaceutical dosage forms.
4.7.2. Application in drug-excipient compatibility study
Compatibility study of MIL with various excipients was ana-
lyzed with the developed method. Compatibility data after
3rd month are shown in Table 5. The assay values of MIL
with all excipients were found to be 99.12–100.62 and
98.14–99.72 at long term and accelerate conditions respec-
tively. The Rf values for all samples at both conditions were
found to be 0.63 ± 0.03. The % RSD for all samples were
less that 2%, indicated that the developed and validated
HPTLC method can be used effectively for preformulation
studies and routine analysis of Milnacipran.
4.8. Advantages of developed method
Extensive literature survey revealed that there is no ofﬁcial
HPTLC method reported in major pharmacopeias like USP,
EP, JP, BP and IP for determination of MIL in bulk and
pharmaceutical formulation. There are few UV-spectroscopic
methods and HPLC methods reported in journal publications
but they have certain limitations like derivatization of samples
or require large amount of sample and/or organic solvents or
sensitive to microgram level. Few methods like gas chroma-
tography–mass spectroscopy, micellar electrokinetic capillary
chromatography, etc. are reported but these methods are
not preferred for routine analysis of MIL in bulk, preformu-
lation studies, formulations and stability studies because of
high cost of analysis and skilled requirement for sample
treatment.
The above literature revealed that all available methods are
sensitive for microgram level only or need some complex reac-
tions or require sophisticated instrument or costly in determi-
nation of MIL. There is a need of a new, simple, rapid, highly
sensitive and economic HPTLC method for determination of
Milnacipran.
It can be seen that this simple and reproducible HPTLC
method has enough sensitivity to evaluate preformulation sam-
ples, stability samples and pharmaceutical dosage form of MIL
at low cost. Thus this presented work will meet the industrial
and research laboratories’ requirements.5. Conclusion
A new, simple, and sensitive HPTLC method has been success-
fully developed and validated for determination of MIL in
bulk and pharmaceutical dosage form. The method was found
to be accurate, precise, and reproducible with good stability
under various processing and storage conditions. In addition,
the method was successfully employed for compatibility testing
of MIL with various excipients for formulation design. Thus
this developed and validated method will help the industries
as well as researchers for their sensitive determination of
MIL rapidly at low cost.Please cite this article in press as: Singhvi, G. et al., Development of a new
bulk, formulation and compatibility study. Arabian Journal of ChemistryAcknowledgments
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